Exchange: NASDAQ·Updated 07:59 PM EST

IONS News

News
all
press releases
Ionis Pharmaceuticals Pushes TRYNGOLZA Access as Insurer Requirements Slow Launch
Ionis Pharmaceuticals (NASDAQ:IONS) is working to accelerate prescriptions for TRYNGOLZA as physicians gain experience with the drug and patients navigate insurance requirements, CEO Brett Monia said at the Jefferies Global Healthcare Conference. Three months into the drug's launch for severe hyper...
MarketBeat
Ionis Pharmaceuticals Pushes TRYNGOLZA Access as Insurer Requirements Slow Launch
Ionis Pharmaceuticals (NASDAQ:IONS) is working to accelerate prescriptions for TRYNGOLZA as physicians gain experience with the drug and patients navigate insurance requirements, CEO Brett Monia said at the Jefferies Global Healthcare Conference. Three months into the drug's launch for severe hyper...
MarketBeat
More News
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Stock analysts at HC Wainwright dropped their FY2026 EPS estimates for Ionis Pharmaceuticals in a note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($3.44) per share f...
MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONSPR NewswireNEW YORK, Nov. 19, 2026 NEW YORK, Nov. 19, 2026...
PR Newswire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities researchers at HC Wainwright cut their Q4 2027 earnings estimates for Ionis Pharmaceuticals in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now expects that the company will post earn...
MarketBeat
IONS expands Tryngolza's European reach as the EU approves its use for sHTG, marking a first for RNA-targeted therapies in this patient population.
Zacks
Guggenheim reduced their price objective on Ionis Pharmaceuticals from $80.00 to $65.00 and set a "buy" rating for the company in a research report on Wednesday...
MarketBeat
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer's...
Business Wire
Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 52-Week Low - Here's Why...
MarketBeat
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride...
Business Wire
Ionis Pharmaceuticals (NASDAQ:IONS) remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CEO Brett Monia said at the UBS Global Biopharma Conference. Monia said physicia...
MarketBeat

Advertisement|Remove ads.